(THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Conjugating the short peptide with various anti-cancer agents allows for. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. $109. 24 million, 48. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. October 13, 2022 07:30 ET | Source: Theratechnologies. stockhouse. Shares of Theratechnologies are up 4. com uses cookies on this site. We also use them to share usage information with our partners. Cookies are used to offer you a better browsing experience and to analyze our traffic. European Headquarters. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. Theratechnologies, Inc. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. THTX | Complete Theratechnologies Inc. GUD | Complete Knight Therapeutics Inc. MONTREAL, Nov. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. It's a different kind of fat that may require a different type of treatment. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. Cookies are used to offer you a better browsing experience and to analyze our traffic. B2Gold Declares Fourth Quarter 2023 Dividend. GlobeNewswire. 4%. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). Get the latest Sernova Corp (SVA) real. com uses cookies on this site. ir@theratech. About TH1902. A high-level overview of Theratechnologies Inc. GlobeNewswire. Stockhouse. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. Track Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. 2 million. Montréal, Québec, Canada . This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. - TH1902 Phase 1 basket trial proceeding as planned. Browse posts by Sector and Subsector. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Senior Director, Communications & Corporate Affairs. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. FAQ – Émetteurs inscrits NOUVEAU. Stockhouse. 75. 25 to $1. Saint-Laurent, Canada. Website. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Oct. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. com uses cookies on this site. TH | September 5, 2023. MONTREAL, Aug. 2. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. ( THTX 3. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Theratechnologies Inc. - On track to meet FY2022. MONTREAL, Dec. Read More. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. FY2023 revenue guidance range set between $90 million and $95 million. By continuing to use our service, you agree to our use of cookies. 81 million for the quarter. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. About Us | Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. View real-time stock prices and stock quotes for a full financial overview. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Stockhouse. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. According to 3 analysts, the average rating for THTX stock is "Buy. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". 521. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. Theratechnologies Announces 1-for-4 Reverse Stock Split. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. stock news by MarketWatch. Theratechnologies Inc. T. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 51 to 200 Employees. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. T. . 25. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Further. MONTREAL, Oct. . Focused on small-cap companies and sectors. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. . Theratechnologies has generated ($1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. 60%. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. FAQ – Utilisateurs de TMX Argent NOUVEAU. By continuing to use our service, you agree to our use of cookies. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. Once expert advice is considered, the Company. Stockhouse. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. T. By continuing to use our service, you agree to our use of cookies. (TH. View real-time stock prices and stock quotes for a full financial overview. With the company starting 2023 with 8,725 employees, that’s an 11. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies had a negative net margin of 36. com uses cookies on this site. . Theratechnologies had a negative net margin of 36. 54% and a negative trailing twelve-month return on equity of 1,116. NCU. We also use them to share usage. European Headquarters. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Theratechnologies to Announce Financial Results for Its First Quarter 2022. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FDA for its IV push form of administration of Trogarzo. The price has fallen in 7 of the last 10 days and is down by -30. By continuing to use our service, you agree to our use of cookies. (THTX) NasdaqCM - NasdaqCM Real Time Price. Headquarters. Find the latest Theratechnologies Inc. 67% from the latest price. Stockhouse. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. - Cash, bonds and money market funds of US$22. Proceeds to Be Used to Redeem All of the Outstanding 5. Volume has increased on the last day along with the price, which is a. Stockhouse. Stockhouse. (“Theratechnologies”) with the Securities and Exchange Commission (the. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. European Headquarters. Theratechnologies Stock Price, News and Company Updates. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Revenues have been growing at an average rate of 10. 33 +0. Montreal-based biopharmaceutical company Theratechnologies Inc. We also use them to share usage. com uses cookies on this site. com. Cookies are used to offer you a better browsing experience and to analyze our traffic. , alpha and beta) for all equities such as Theratechnologies. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. 4. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Stockhouse. By continuing to use our service, you agree to our use of cookies. 17% from a day low at $1. 71%. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. Cookies are used to offer you a better browsing experience and to analyze our traffic. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. 38. TH | July 20, 2023. Theratechnologies Inc. Further. Wainwright NASH Investor Conference. Gary Littlejohn. 49) by $0. Trogarzo® and. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. First Quarter Fiscal 2022 Financial Results. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. TH 48% v4,15M c1. Theratechnologies, Inc. Theratechnologies is pepped up on peptides. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. 08 (+6. com. com uses cookies on this site. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies Inc. 03) EPS for the quarter, beating the consensus estimate of ($0. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. Theratechnologies inc. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. com uses cookies on this site. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . stock news by MarketWatch. Unveiling Silvercorp's golden potential at the Ying Mining District. com. Competitors: Unknown. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Thank you. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Theratechnologies inc. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. We also use them to share usage. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. Betteryear2. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The reported ($0. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. By continuing to use our service, you agree to our use of cookies. The business had revenue of $27. View real-time stock prices and stock quotes for a full financial overview. . (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. 08). TH | Complete Theratechnologies Inc. Stockhouse. Theratechnologies . com. 67, which is an increase of 1,144. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. We changed the address of the Stockhouse website from to stockhouse. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. 63. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. ET. Katana shareholders will. Who is Theratechnologies. Further. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. THTX | Complete Theratechnologies Inc. Theratechnologies Inc. stock price gained 1. The company reported ($0. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. We currently market. MONTREAL, Oct. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company"). (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. By continuing to use our. Theratechnologies Provides Details About R&D Day Webcast. If you have HIV, it's important to know the difference. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH | May 19, 2023. THERATECHNOLOGIES INC. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 514-336-7800. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. It is the Company’s proprietary. Stockhouse. Theratechnologies develops and commercializes innovative therapies. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. stock news by MarketWatch. (2013-04-03 | TSX:TH) Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. Biopharmaceutical company Theratechnologies Inc. Apr 14, 2020, 8:30 a. Patient assistance: 833-238-4372. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. . Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Theratechnologies Inc. 's motion for leave to commence. Further. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. During the last trading day the stock fluctuated 4. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Gary Littlejohn Stockhouse. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . Pour les émetteurs. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. 04) earnings per share (EPS) for the quarter. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. The Theratechnologies Inc. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. 72%. (2013-04-03 | TSX:TH) Theratechnologies Inc. is an employee of TaiMed Biologics USA, Inc. com uses cookies on this site. W. By Nick Paul Taylor Jul 12, 2023 8:57am. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. 54% and a negative trailing twelve-month return on equity of. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Further. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. It is the Company’s proprietary peptide linked to. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. . . The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. 5%. sBLA for F8 formulation of tesamorelin submitted to FDA. Stockhouse. RESSOURCES. : Renegotiated Lease to Generate Substantial Annual Savings. Investor Relations. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. Market Cap. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH Stock Message Board for Investors. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Christian Marsolais, Ph. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. 86 million for the quarter. (TH.